Skip to content

Clinical randomized controlled trial study of Meridian flow injection warming through scraping combined with Chinese medicine retention enema in the treatment of chronic pelvic inflammatory disease

Clinical randomized controlled trial study of Meridian flow injection warming through scraping combined with Chinese medicine retention enema in the treatment of chronic pelvic inflammatory disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000891
Enrollment
Unknown
Registered
2025-05-06
Start date
2023-03-19
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pelvic inflammation

Interventions

experimental group:Treatment with Meridian Flow Injection Warm Passage Scraping Combined with Traditional Chinese Medicine Enema on the Basis of Routine Nursing Care
control group:Routine care

Sponsors

Foshan Women and Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) met the diagnostic criteria for chronic pelvic inflammatory disease; (2) had an age range of 20-55 years old had a history of sexual intercourse and were not yet menopausal;(3) signed an informed consent form and agreed to the treatment; (4) did not receive any other related treatment during the study period.

Exclusion criteria

Exclusion criteria: (1) Patients who did not meet the inclusion criteria and did not follow the prescribed course of treatment; (2) Patients who have recently been treated with related drugs resulting in the inability to judge the efficacy of the treatment; (3) Patients with serious diseases of the heart liver kidney and hematopoietic system; (4) Patients who are unable or unwilling to cooperation; (5) women who are pregnant or preparing for pregnancy recently and breastfeeding women; (6) those who have turned into acute pelvic inflammatory disease in critical condition; and those who have obvious concurrent or (6) Those who have turned to acute pelvic inflammatory disease in critical condition; those who have obvious concurrent or comorbidities.

Design outcomes

Primary

MeasureTime frame
Evaluation of efficacy in relieving pelvic pain;

Secondary

MeasureTime frame
Chinese Medicine Symptom Score;Assessment of efficacy of localized pelvic signs;

Countries

China

Contacts

Public ContactLi Liu

Foshan Women and Children's Hospital

ouyuyi@fsfy.com18022230080

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026